Abstract
Long-term treatment with drugs involves crucial but often neglected problems because in most cases the therapeutic effect has been assessed with purely clinical procedures. This judgement depends on criteria of different value, for example on changes in clinical symptoms or in laboratory data, in some other cases on changes in plasma drug concentrations. This is explained by the following examples:
-
1.
Effective digitalization can be seen only with respect to improvement of clinical signs such as reduction of body weight and disappearance of oedema and of dyspnoea. The glycoside plasma level and shortening of systolic time intervals are uncertain criteria with respect to the restitution of compensation.
-
2.
Prophylaxis of thrombo-embolic diseases with drugs is possible by laboratory control of the coagulation potential. The methods used for control of coagulation factors, however, lead to uncertain dosage regimen calculations. Nevertheless, control of medication will be better because it is oriented to more objective parameters than that of the first example.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Beerman, B., Hellstrom, K., and Rosen, A.: Fate of orally administered 3H-digitoxin in man with special reference to the absorption; Circulation 43 (1971), 802–861
Duhne, D. W., Greenblatt, D. J., Koch-Weser, J.: Reduction of digoxin toxicity associated with measurement of serum levels; Ann. intern. Med. 80 (1974), 516–519
Gjerdrum, K.: Digitoxin studies—serum concentration during digitalization, maintenance therapy, and withdrawal. Estimation of proper maintenance dose; Acta Med. Scand. 191 (1972), 25–34
Haustein, K.-O.: Methoden zur Bestimmung von Herzglykosiden: Möglichkeiten und Erfahrungen; Zschr. med. Labor.-Diagn. 20 (1979), 99–110
Haustein, K.-O., Richter, M., und Vogel, G.: Zur Optimierung einer Langzeitbehandlung mit Phenprocoumon; Dt. Gesundh.-Wesen 30 (1975), 1514–1518
Haustein, K.-O., Richter, M., Vogel, G., und Mittag, E.: Individualization of drug dosage during longterm treatment with phenprocoumon (Falithrom®); Int. J. clin. Pharmacol. 16 (1978), 372–276
Haustein, K.-O., Fiehring, H., Oltmanns, G., Femmer, K.: On the clinical pharmacology of talinolol, a new ßi-adrenoceptor blocking agent; Int. J. clin. Pharmacol. 17 (1979), 465–470
Heni, N., Glogner, P.: Pharmacokinetics of phenprocoumon in man investigated using a gas chromatographic method of drug analysis; Naunyn-Schmiedeberg’s Arch. Pharmacol. 293 (1976), 183–186
Hüthwohl, B., Jähnichen, E.: Displacement of phenprocoumon (Marcumar®) from albumin by sulfonylurea compounds, suramin and ioglycamic acid; Naunyn-Schmiedeberg’s Arch. Pharmacol. 273 (1972), 204–212
Husted, S., Andreasen, F., Foged, L.: Increased sensivity to phenprocoumon during methyltestosterone therapy; Europ. J. clin. Pharmacol. 10 (1976), 209–216
Koch-Weser, J.: The serum level approach to individualization of drug dosage; Europ. J. clin. Pharmacol. 9 (1975), 1–8
Koup, J. R., Greenblatt, D. J., Jusko, W. J., Smith, T. W., Koch-Weser, J.: Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses; J. Pharmacokin. Biopharm. 3 (1975), 181–192
Lowenstein, J. M., Corrill, E. M.: An improved method for measuring plasma and tissue concentrations of digitalis glycosides; J. Lab. clin. Med. 67 (1966), 1048–1053
Lukas, D. S.: Some aspects of the distribution and disposition of digitoxin in man; Ann. N. Y. Acad. Sci. 179 (1971), 338–361
Meinertz, T., Gilfrich, H.-J., Groth, U., Johnen, H.-G., Jähnichen, E.: Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine; Clin. Pharmacol. Ther. 21 (1977), 731–735
Nyberg, L., Andersson, K.-E., Bertler, A: Bioavailability of digoxin from tablets. II. Radioimmunoassay and disposition pharmacokinetics of digoxin after intravenous administration. Acta Pharmacol. Suecica 11 (1974), 459–470
Oliver jr., G. C., Parker, B. M., Brasfield, D. L., Parker, C. W.: The measurement of digitoxin in human serum by radioimmunoassay; J. clin. Invest. 47 (1968), 1035–1072
Owren, P. A.: Critical study of tests for control of anticoagulant therapy; Thrombos. Diathes. haemorrh. (Stuttg.) 9 (1963), 74–80
Quick, A. J.: The development and use of prothrombin test; Circulation 19 (1959), 92–98
Rabkin, S. W., Grupp, G.: A two compartment open model for digitoxin pharmacokinetics in patients receiving a wide range of digoxin doses; Acta Cardiol. 30 (1975), 343–351
Richter, M.: Zur fluorimetrischen Bestimmung von Phenprokoumon im Blutplasma; Zbl. Pharm. 115 (1976), 611–614
Seiler, K., Duckert, F.: Properties of 3-(1-phenyl-propyl)-4-oxycoumarin (Marcoumar®) in the plasma when tested in normal cases and under influence of drugs; Thrombos. Diathes. haemorrh. (Stuttg.) 19 (1968), 389
Smith, Th. W., Haber, E.: Clinical value of the radioimmunoassay of the digitalis glycosides; Pharmacol. Rev. 25 (1973), 219–228
Solomon, H. M., Reich, S., Spirit, N., Abrams, W. B.: Interactions between digitoxin and other drugs in vitro and in vivo; Ann. N. Y. Acad. Sci. 179 (1971), 362–369
Vesell, E. S.: Factors causing interindividual variations of drug concentrations in blood; Clin. Pharmacol. Ther. 16 (1974), 135–148
Vöhringer, H. F., Rietbrock, N.: Metabolism and excretion of digitoxin in man; Clin. Pharmacol. Ther. 16 (1974), 796–806
Wagner, J. G.: Fundamentals of clinical pharmacokinetics. 1st Ed., 461 pp., Drug Intelligence Publications, Inc. Hamilton/Ill. 1975
Wagner, J. G., Northan, J. I., Ahway, C. D., Carpenter, O. S.: Blood levels of drug at the equilibrium state after multiple dosing; Nature 207 (1965), 1391–1402
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer Fachmedien Wiesbaden
About this chapter
Cite this chapter
Haustein, KO. (1980). Individual pharmacokinetic parameters in patients on long-term treatment. In: Rietbrock, N., Woodcock, B.G., Neuhaus, G. (eds) Methods in Clinical Pharmacology. Methods in clinical pharmacology, vol 1. Vieweg+Teubner Verlag, Wiesbaden. https://doi.org/10.1007/978-3-663-14027-6_17
Download citation
DOI: https://doi.org/10.1007/978-3-663-14027-6_17
Publisher Name: Vieweg+Teubner Verlag, Wiesbaden
Print ISBN: 978-3-528-07902-4
Online ISBN: 978-3-663-14027-6
eBook Packages: Springer Book Archive